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1.  INTRODUCTION 
The concept of the blood-brain barrier (BBB) was developed late in the last 
century on the basis that certain dyes did not accumulate in the brain, in contrast to other 
organs.  Just after the middle of this century, research demonstrated that the BBB resides 
in the endothelium of the brain microvessels, represented a significant surface area of 
exchange between blood and brain (around 12 m2), and was, however, the primary 
barrier to drug and peptide entry into the brain (Pardridge, 1994). The modern view of 
the BBB may be regarded as a dynamic barrier where many of its characteristics 
potentially may be up or down regulated in normal as well as in disease states.  
Several specific characteristics of the brain endothelium participate in formation 
of this barrier, including anatomical or morphological features illustrated in Figure 1.  In 
contrast to peripheral endothelial microvessels, the endothelium comprising the BBB has 
no fenestrations and a reduced number of pinocytic vesicles suggesting that bulk transfer 
and transcytotic mechanisms for moving macromolecules are not well elaborated at the 
BBB. However, as reviewed below, specific, unidirectional movement of a limited 
number of macromolecules does occur at the BBB (Broadwell and Banks, 1993). The 
cells also exhibit the presence of unusually tight intercellular junctions (Reese and 
Karnovsky, 1967; Brightman and Reese, 1969) which effectively "seal" the apposing 
intercellular membranes of the endothelial cells together and confer a high membrane 
resistance (Crone and Olesen, 1982).  Thus, the passive movement of macromolecules 
and hydrophilic compounds paracellularly is effectively blocked and forces substances to 
undergo transcytotic transport.  The brain endothelial cells also contain many 
mitochondria, indicating that the barrier between blood and brain can contribute to 
biotransformation of xenobiotics (Pardridge, 1983, Ghersi-Egea et al., 1995; Minn et al., 
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1991). Cells surrounding the brain endothelium (i.e., neurons, astrocytes and pericytes), 
as well as the basal lamina, seem to contribute to the stability and the barrier 
characteristics of the brain endothelial cells.  These cell-cell interactions appear to be via 
the secretion of trophic factors rather than direct physical contact (Joo, 1996; Graguera et 
al., 1993; Claudio et al, 1995; Ment at al. 1995). 
In order to understand the transport mechanisms of the BBB, in vivo, in situ, and 
in vitro systems have been developed and are now in use to explore the biochemical and 
molecular basis of the BBB.   While in vivo or in situ studies can provide an indication 
of the delivery potential and pharmacological consequences in animal models, the in 
vitro systems (i.e., isolated brain capillaries, cell cultures, etc.) offer promising tools in 
order to characterize properties specific to brain endothelial cell transport and 
metabolism at the cellular, biochemical, and molecular levels (Audus et al., 1996).  
Addressing the application, advantages, and disadvantages of different experimental 
systems is beyond the scope of this chapter and interested readers are directed to recent 
reviews (Audus et al., 1996; Smith, 1996).  
Further discussions in this chapter will survey the membrane transport processes 
that currently allow drugs and macromolecules to permeate the BBB.  A number of 
transcellular transport systems in brain endothelia exist for the transport of vital nutrients 
and waste products between the blood and the central nervous. The presence of an efflux 
pump, the multidrug resistant gene product  1 (MDR1), an overexpressed P-
glycoprotein, compounds the picture of the BBB and is included here as a significant 
problem that must be overcome in many drug delivery strategies.  We also include 
mention of several less well-characterized systems which might contribute to 
transporter-targeted delivery strategies in the future. We hope this discussion might 
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stimulate researchers to develop a better knowledge of natural transport systems at the 
BBB and underscore more strongly their possible primordial role in drug delivery and 
therapeutic efficacy. 
 
2. BLOOD BRAIN BARRIER TRANSPORT  
2.1. Carrier-Mediated Transport 
Carrier-mediated transport may be described as either facilitative which is 
saturable, stereoselective, and energy-independent, or active which is saturable, 
stereoselective and directly dependent on energy expenditure by the cell.  Several carrier 
mechanisms have been described at the BBB and now include both active and 
facilitative types as summarized in Table 1. Only a few of these carriers have been 
extensively characterized and cloned. For some, such as the neutral amino-acid carrier, 
their utility in drug delivery to the brain is well known.  
 
 2.1.1. Carriers and efflux systems for low molecular weight molecules 
At least five D-glucose transporters have been described (Thorens, 1996). From 
the earliest studies, it appeared that D-glucose crossed the BBB easily and 
stereospecifically, thanks to a high density of facilitative type transporters. Discrepant 
results have been published concerning the reported affinity constants of glucose for 
“its” transporter, GLUT-1 (Audus et al., 1992), and could arise from the overlapping 
specificities of  the various transporters. A recent study has described a sodium-
dependent, active transport of glucose at the BBB that apparently functions in parallel to 
the facilitative GLUT-1 transporter (Nishizaki et al. 1995). 
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The GLUT-1 transporter is inhibited by barbiturates (Honkanen et al., 1995) and 
its gene expression can be controlled by cerebrolysin (Boado, 1995). Although there is a 
relatively low affinity of the substrate D-glucose for the GLUT-1 carrier (Km in the mM 
range), no drugs have been shown to be competing substrates. There are a few 
indications that GLUT-1 can transport substrates other than D-glucose.  As examples, 
glucosylation of few peptides has been shown to increase their transport across the BBB 
and the evidence seemed to indicate that GLUT-1 was responsible for this transport (Polt 
et al., 1994). Additionally, the oxidized form of ascorbic acid has been shown to be 
transported by the GLUT-1 carrier (Agus et al., 1997). Attempts have also been made to 
couple chemotherapeutics with glucose (e.g., glucose-chlorambucil derivatives) only to 
find that, while the agents inhibit the GLUT-1 transporter, the agents are not transported 
(Halmos et al., 1996). Despite some positive observations, GLUT-1 does not appear to 
be an obvious carrier of choice for the drug delivery into the brain. 
Saturable and bidirectional carriers for monocarboxilic acids have been decribed 
at the BBB and are responsible of the transport of L-lactate, L-acetate and L-pyruvate, 
valproic acid, salicylic acid and saturated fatty acids (Conn et al., 1983; Adkison and 
Shen, 1996; Gerhart et al., 1997).   In general, these carriers have been more studied in 
intestinal cells like Caco-2 cells and are better known in that cell type (Tamai et al., 
1995; Takanaga et al.,1994).  Drugs such as valproic acid inhibit the uptake of short-
chain monocarboxylic acids such as lactate, acetate and pyruvate at the BBB. However, 
the uptake of valproic acid is not inhibited by short-chain monocarboxylic acids.  Rather, 
the passage of valproic acid across the BBB appears to occur through a medium-chain 
fatty acid transporter (Adkinson and Shen, 1996). Therefore, it appears that multiple 
carriers for monocarboxylic acid compound are probably expressed at the BBB and 
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show overlaps in substrate selectivity. Specific antibodies as well as molecular probes 
may allow a better characterization of the transporters of monocarboxylic acid 
compounds and eventually demonstrate their importance in the delivery of drug across 
the BBB. 
Neutral amino-acid carriers have proven to be capable of transporting many amino 
acids, drugs and endogenous compounds with similar stuctures. Leucine, cysteine, serine, 
alanine, phenylalanine, L-dopa, L-tryptophan, the alkylating agent melphalan, the 
antiepileptic drug gabapentin, the muscle relaxant baclofen, the neurotoxin beta-N-
methylamino-L-alanine are all examples of agents shown to be substrates of neutral 
amino-acid carriers (Begley, 1996, De Boer and  Breimer, 1994; Smith et al. 1992; 
Oldendorf and Szabo, 1976). Various forms of neutral amino-acid carriers have been 
described (Sanchez-del-Pino et al., 1995; Zerangue et al., 1996). For instance, the carrier 
for large neutral amino-acids (LNAA) mainly transports phenylalanine with a high 
affinity (Km about 10 µM) and is sodium-independent. Since LNAA carrier is saturated 
under normal conditions by neutral amino acids present in blood, substrate competition 
does occur in vivo and does impair delivery of lower affinity substrates (Shulkin et al., 
1995). The large neutral amino acid carriers, located on the luminal and abluminal 
membranes of the brain endothelial cells, appear to be subject to regulation by 
endogenous compounds such as oxoproline (Lee et al., 1996) and vasopressin (Reichel et 
al., 1996).   
In contrast to dopamine, L-dopa is transported across the BBB by the LNAA 
carrier and is readily biotransformed into the brain to dopamine. At present, the pro-drug 
L-dopa represents the best example of drug delivery mediated by a facilitated amino acid 
carrier at the BBB. Alkylating agents, mephalan and the nitrogen mustard, DL-NAM, 
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have also shown to be substrates of LNAA carrier at the BBB (Begley, 1996; and Takada 
et al., 1992).  The affinity of DL-NAM for the LNAA carrier is 100 times higher than 
mephalan because the addition of a naphtoic side chain.  LNAA carriers show 
stereospecific activity for the S-isoforms of phenylalanine derivatives prepared as NMDA 
receptor antagonists.  As an example, L-4-chlorokynurenine might be a useful prodrug for 
brain delivery of Glycine-NMDA receptor antagonist since it is rapidly transported across 
the BBB by the LNAA carrier and enzymatically converted in brain parenchyma to the 
therapeutic form, 7-chlorokynurenic acid (Hokari et al., 1996). The cytotoxic agent 
acivicin causes neurotoxicity due to its broad penetration into the brain, largely mediated 
by LNAA carriers. Thus, acivicin derivatives showing a lower affinity for LNAA carriers 
could exhibit a lower CNS toxicity (Chikhale et al., 1995a). 
Other neutral amino-acid carriers (i.e, types A, ASC and N) showing more 
selectivity for small neutral amino-acid and a sodium dependence, have been described 
at the BBB (Zerangue et al. 1996; Sanchez-del-Pino et al., 1995).   These amino acid 
carriers do have overlaps in amino acid recognition.  For instance, the BBB transport of 
L-glutamine, mainly found in the cerebrospinal fluid, has been investigated and there has 
been an indication that two neutral amino-acid carriers were involved in the L-glutamine 
transport: a Na-independent system L and a Na-dependent system N (Keep and Xiang, 
1995). Taking into consideration all of these examples, the neutral amino acid carriers 
continue to have the potential for brain delivery of therapeutic agents.  Nevertheless, 
progress has yet to be made regarding the definition of the broad functions, affinities, 
and the specificities of all of BBB neutral amino-acid carriers. 
Basic amino-acid and acidic amino-acid transporters have been shown to transport 
asparagine, lysine and aspartate and glutamate across the BBB (Oldendorf, 1971; Benrabh 
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and Lefauconnier, 1996). Amine transporters are able to transport choline across the BBB 
(Galea and Estrada, 1992). The existence of nucleoside transporters has also been 
demonstrated (Joo, 1996).  These latter carriers are able to transport the purines 
adenosine, guanosine, inosine and the pyrimidine uridine across the BBB (Cornford and 
Oldendorf, 1975; Thomas and Segal, 1997). Thiamine and thyroid transporters are able to 
transport thiamine, vitamins such as folates and ascorbic acid, and T3 across the BBB, 
respectively (Greewood et al., 1982; Joo, 1996). Once more, molecular and biochemical 
characterizations of these transporters will allow a better understanding of their potential 
for exploitation in drug delivery. 
Many drugs have been shown to cross the brain endothelial cells poorly in spite 
of their favorable coefficient partitions (i.e., relatively lipophilic compounds). In fact, 
many drugs and peptides are pumped outside the cells by active transporters which are 
present in many cell types (Lum and Gosland, 1995). These transmembrane pumps 
contribute to the resistance to anticancer agents and probably psychotropic drugs in both 
normal and tumor tissues. P-glycoprotein (P-gp) is actually the most documented efflux 
pump in resistant cell lines as well as in normal tissues (Stein, 1997; Lum and Gosland, 
1995) and is responsible for the multdrug resistance type 1 (MDR1) phenotype in vitro 
as well as in vivo (Lum and Gosland 1995; Huang et al., 1997).  Carcinogens and various 
xenobiotics are capable of co-inducing the both expression of P-gp, as well as some 
cytochrome P-450 isozymes, in normal tissues as well as in cancer resistant cell lines 
(Burt and Thorgeirsson, 1988; Thorgeirsson et al., 1991). Inhibition of the efflux 
mechanism by the so-called reversing agents allows an increased accumulation of P-gp 
substrates inside the cells (Wigler, 1996).  The P-gp of the BBB has been shown to play 
a sometimes dominant role in the efficacy of many drugs in the central nervous system 
Rochat, B. and Audus, K.L. (1999) Drug disposition and targeting: Transport across the blood-brain barrier.  Pharm. 
Biotechnol. 12, 181-200.  PMID: 10742975.  Publisher’s official version: <http://dx.doi.org/10.1007/0-306-46812-
3_6>.  Open Access version:  http://kuscholarworks.ku.edu/dspace/. 
 
(Schinkel et al., 1994; 1996).  In humans, the activity of the brain P-gp is about one-
fourth that expressed in the gut (Silverman and Schrenk, 1997).  
The number and diversity of drugs shown to be substrates of the P-gp suggests 
that, like cytochrome P-450, the specificity of P-gp is very broad (Gottesman and Pastan, 
1993).  In the near future, other drug efflux systems (MDR-like pumps) are likely to be 
discovered and characterized at the BBB. Clearly, not all drugs have the same affinity for 
MDR1 present at the BBB, MDR1 systems do vary somewhat among species (Schinkel 
et al., 1994; 1996), and there are some indications that MDR1 may vary in localization at 
the blood-brain barrier, particularly in the human, where there is conflicting evidence of 
MDR1 localization from the typical luminal membrane (Stewart et al., 1996) to an 
abluminal and astrocytic foot location (Pardridge et al., 1997).  The multidrug resistance 
protein, MRP, which has been described in cancer-resistant cell lines as well as normal 
tissues (Kavallaris, 1997; Berger et al., 1997; Barrand et al., 1997), is expressed and 
functional at the BBB (Miller et al., 1997). In cancer cell lines, other MDR transporters, 
different from the MDR1 and MRP, have already been identified (Izquerdo et al., 1996; 
Huang et al., 1997; Lee et al., 1997). 
It appears that, in most instances, lipophilic drugs are substrates of an ATP-
dependent efflux pump, MDR1, an overexpressed P-glycoprotein (P-gp) localized at 
luminal membranes of the brain endothelial cells. Structurally diverse compounds are 
able to inhibit, sometimes in a competitive manner, the P-gp activity. Known substrates 
include vinblastine, reserpine, verapamil, trifluoperazine, amiodarone, daunomycin, 
progesterone, propafenone, and quinidine (Drion et al., 1996; Wigler, 1996; Kavallaris, 
1997; Stein, 1997).  
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As transporters, drug efflux systems remain important BBB targets that must be 
neutralized to realize delivery of a wide variety of therapeutic agents. Cyclosporine A is 
able to inhibit completely the P-gp activity (Wigler, 1996) and the cyclosporine D 
derivative, SDZ PSC 833, has also been used in vivo and in vitro and show a potent P-gp 
inhibition. The pipecolinate derivative of cyclosporine D, VX-710, which is able to 
inhibit P-gp, showed a stronger inhibition of the MRP activity effect than either 
verapamil or cyclosporin A (Germann et al., 1997).   The ATPase portion of the P-gP 
can be inhibited by bafilomycin A1.   P-gp ATPase activity can  be stimulated by 
colchicine, verapamil and trifluoperazine (Sharom, 1995).  The phospholipids 
surrounding the P-gp ATPases have been identified and could play an important role in 
its activity. It has been suggested that the inhibition of the P-gp activity by so-called 
fluidizers could occur by perturbing the lipid intregrity around the P-gp and its ATPase 
(Drori et al, 1995).    
 
2.1.3. Peptide carriers 
A limited but growing body of research has been focused on saturable carriers for 
selected peptides at the BBB. These carriers are both unidirectional, either transporting 
peptides out of the brain or into the brain, and bidirectional (Banks and Kastin, 1996).  
Carrier systems for small peptides at the BBB are summarized in the Table 2.  At 
present, there appear to be no carriers of peptides larger than 10 amino-acids at the BBB 
and those larger peptides would be expected to undergo transcytosis (Broadwell and 
Banks, 1993).   At present, many of these carrier mechanisms lack sufficient 
characterization to propose precise roles for the mechanisms in drug delivery schemes.  
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Several small peptides have been shown to be apparent substrates of P-gp efflux 
at the BBB (Sharma et al., 1992; Sarkadi et al., 1994; Chikhale et al., 1995b).  However, 
independent of P-gp, the unidirectional transport of peptides such as corticotropin-
releasing hormone (CRH) have been shown to be mediated by an active transporter and 
dependent on calcium channels (Martins et al., 1996 and 1997).    Similary, a number of 
other small peptides also have distinct, independent transport systems to move the 
peptides from the brain into the systemic circulation.  Among these are small tyrosinated 
peptides, Met-enkephalin and Tyr-MIF-1 (Banks and Kastin, 1997; Banks et al., 1994).  
The transporter for these latter peptides is notable for being sensitive to ethanol which 
can enhance the brain Met-enkephalin concentration (Plotkin et al., 1997).   A separate 
efflux system has also been described for RC-160, a somatostatin analog (Banks et al., 
1994) and arginine vasopressin (Begley, 1996).   
In in vivo experiments, D-[Ala1]-peptide T amide is transported from blood to 
brain by a saturable system (Barrera et al., 1987).  Using intraventricular injections of 
peptide T, the transport out of the brain was not saturable indicating a specific 
localization of the carrier at the membrane of the endothelial cells.  Studies employing 
intravenous injection of radiolabelled leptin revealed the presence of a saturable blood-to 
brain transporter (Banks et al., 1996).  Similar to peptide T, no saturable transport of 
radiolabelled leptin out of the brain was observed.  Neurotensin is another representative  
small peptide that also has shown only unidirectional transport into the brain (Banks et 
al., 1995).  
Some of the opioid peptides, including deltorphins, cross the BBB rather 
effectively and experiments performed with isolated bovine brain microvessels indicate 
presence of a naloxone-sensitive carrier (Fiori et al., 1997).  Preloading the microvessel 
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preparations with L-glutamine can also transiently stimulate of deltorphin uptake 
suggesting some interrelationships with amino acid transport at the BBB.  The delta 
opioid receptor-selective [D-Penicillamine-2,5] enkephalin (DPDPE) has been shown to 
penetrate the brain by a saturable system (Thomas et al., 1997). The uptake system for 
DPDPE, which does not involve the large amino acid transporter, has yet to be fully 
characterized. Transport of  leucine-enkephalin across the BBB has also been 
demonstrated in vivo and exhibited a saturable mechanism (Zlokovic et al., 1987).  The 
potential relationships among the carriers for opioids at the BBB have not been resolved.  
The possibility obviously exists, however, for the design and development of opioid 
peptide therapeutics that target BBB carriers and achieve improve brain delivery 
(Thomas et al., 1997). 
The last group of peptide carriers to be mentioned facilitate peptide distribution 
across the BBB in both directions.  Bidirectional and saturable transporters exist for 
peptides such as luteinizing hormone-releasing hormone (LHRH; Barrera et al., 1991) 
and Interleukin-1 alpha (Banks et al., 1989).  Different transporters, sodium dependent or 
independent, have also been identified for glutathione (Kannan et al., 1996). 
  
2.2 Transcytosis 
Macromolecules may cross the brain microvessel endothelial cells by 
transcytosic mechanims mediated by luminal surface receptors (Audus et al., 1992; 
Broadwell and Banks, 1993).  While the role of plasmalemmal vesicles as transcytotic 
carriers through the endothelium was postulated in the 1960’s but the use of a 
combination of a non-transportable moiety with a natural macromolecule, a chimeric 
drug delivery system, recognized by membrane receptors mediating transcytosis at the 
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BBB was not proposed until the late 1980’s (Pardrige et al., 1987).  Subsequently, 
several receptor systems mediating transcytotic processing through the BBB have been 
described and are summarized in the Table 3.  In several instances, these transcytotic 
systems have been explored as mechanisms to target and facilitate the delivery of 
therapeutic entities to brain capillary endothelial cells and eventually the brain. 
A high rate of  transcytosis of insulin in brain capillary endothelial has been 
reported in vivo and suggests that the insulin receptor could be an effective target for 
drug delivery into the brain (Duffy and Pardridge, 1987; Podulso et al., 1994).   Related 
peptides, insulin-like growth factor I and II, also show significant brain levels following 
injection into the carotid artery of rats (Rheinhardt and Bondy, 1994).   Native insulin 
has been used as a carrier of horseradish peroxidase, a protein which crosses the BBB 
very slowly (Fukuta et al., 1994).  The difficulty in using native insulin as carrier is the 
associated hypoglycemia.  For this reason, insulin fragments have also been examined as 
carriers and have shown some promise (Fukuta et al., 1994).   
Transferrin is another natural polypeptide that like, insulin, crosses the BBB by a 
receptor-mediated system (Broadwell et al., 1996).   While native transferrin has also 
been considered as a potential chimeric carrier, most current efforts focus on the use of 
monoclonal antibodies directed at specific receptor systems.  Monoclonal antibodies 
generated against transferrin or insulin receptors have been shown to cross the BBB 
(Friden et al., 1996; Pardridge et al., 1995b).   Due to its  rapid transcytosis the insulin 
receptor monoclonal antibody has been proposed as an effective drug delivery vector and 
potential diagnostic tool and has been demonstrated in a primate model (Wu et al., 
1997). The murine OX26 monoclonal antibody to rat transferrin receptor was also 
successfully used as vector in order to increase the delivery of brain-derived 
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neurotrophic factor and polyamide nucleic acids across the BBB (Pardridge et al., 1994; 
Pardridge et al., 1995a). On comparison, horseradish peroxidase and native transferrin 
complexes do cross  the BBB more efficiently than horseradish peroxidase and OX26 
antibody complexes.   After i.v. injection in rat, some differences in intracellular and 
extracellular distributions in brain were observed indicating that fates in the central 
nervous system of delivery systems employing native transferrin and monoclonal 
antibodies to the transferrin receptor will differ (Broadwell et al., 1996).   Indications are 
that both insulin and transferrin receptor targeting monoclonal antibodies could be useful 
for non-invasive delivery of therapeutic entities to the brain.  
Other endogenous substances appear to undergo receptor-mediated transcytosis 
at the BBB and their receptors  may be considered potential delivery targets.  Low 
density lipoprotein (LDL) is specifically transcytosed across brain capillary endothelial 
cells (Dehouck et al., 1997). LDL is transcytosed by a receptor mediated system which 
can be upregulated by the depletion of cholesterol in the astrocyte:endothelial cell co-
cultures.   A receptor-mediated transport process has also been reported for the amyloid 
beta-protein suggesting that sources outside the nervous system could contribute, at least 
partially, to the cerebral A beta-amyloid deposits seen in Alzheimer's patients (Podulso 
et al., 1997).  Finally, leptin, a protein synthesized by adipose tissue as signal of satiety, 
penetrates the BBB via trancytosis mediated by specific receptors (Golden et al., 1997).  
Several proteins have been shown to undergo adsorptive transcytosis at the BBB,  
however, the precise specificity and therefore targeting potential is not well developed 
for this group.  A recent report indicates that the C-terminal structure and basicity of 
peptides seems to be important for the saturable uptake by an adsorptive-mediated 
endocytosis system at the BBB (Tamai et al., 1997).   The endogenous cationic protein, 
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histone, is also capable of crossing the BBB via an adsorptive transcytotic system 
(Pardridge et al., 1989).  Natural proteins such as immunoglobulin G and albumin have 
been shown to cross the BBB with low permeability surface area products, 
approximately about 25 and 330 times less than the BBB permeability of transferrin and 
insulin, respectively (Podulso et al., 1994).   Although albumin transcytosis apparently 
does not involve a receptor-mediated system (Vorbrodt and Trowbridge, 1991), the more 
rapid rate of immunoglobulin G transfer suggests the potential of a transport mechanism 
(Podulso et al., 1994). Cationionized albumin, with a greater pI than the native albumin, 
enters more readily into the brain and seems to be a tool to study the adsorptive-
mediated endocytosis at the brain endothelial cells (Kumagai et al., 1987).  Selected 
lectins undergo transcytosis at the BBB.  Complexes of horseradish peroxidase and 
wheat germ agglutinin, for example, penetrate the brain 10 times higher than horseradish 
peroxidase alone via a probable non-specific adsorptive (Villegas and Broadwell, 1993; 
Banks and Broadwell, 1994).  
It appears that the complexing of a therapeutic agent with a carrier recognized by 
brain capillary specific endothelial cell receptors can provide a choice for some drug 
delivery strategies since the complex may, in some instances such as transferrin, 
selectively target the BBB (Friden, 1994).  Due to the probable differing fates, structures, 
and capacities for complexation of  the carrier molecules, a single carrier system will not 
be practical.  Thus, the precise determination of chemical structures recognized by BBB 
receptors mediating trancytosis should continue to be a fruitful area of research in the 
future. 
 
3. SUMMARY AND FUTURE PERSPECTIVES 
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 The restrictive permeability properties of the BBB remain a challenge to 
providing sufficient drug delivery into the central nervous system.   Basic research in the 
past few decades surveyed here has revealed, however, that the BBB exhibits an array of 
specific transport systems for both conventional low molecular weight nutrients and 
hormones, as well as limited selection of systems for natural peptides and proteins.    
Future success in exploiting these transport processes is now dependent, to some degree, 
on incorporating the advances in cellular, biochemical and molecular biology into 
thinking about targeting natural transporters to facilitate drug delivery into the central 
nervous system. 
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Figure Captions 
 
Figure 1.   Anatomical and morphological characteristics of endothelium of the blood-
brain barrier and the peripheral vasculature.  (Reprinted from Audus and Borchardt, 
1991 with permission from Springer-Verlag GmbH & Co. KG, Heidelberg.) 
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Table 1.  Blood-brain barrier transport systems for nutrients and low molecular weight organic molecules. 
_______________________________________________________________________________________________________________ 
Carrier   Type   Substrate   Direction  Reference 
_______________________________________________________________________________________________________________ 
A amino acid   active   alanine    brain-to-blood  Komura et al., 1996 
Acidic amino acid  facilitated  glutamate   blood-to-brain  Benrabh and Lefauconnier, 1996 
Amine    active   choline      Galea and Estrada, 1992 
Basic amino acid  facilitated  arginine      Oldendorf, 1971 
Basic organic molecules    mepyramine      Yamazaki et al., 1994 
Biotin    facilitated   biotin    bidirectional  Shi et al., 1993 
Carnitine   facilitated  carnitine   brain-to-blood  Mroczkowska et al., 1997 
Medium-chain fatty acid    valproic acid      Adkison and Shen, 1996 
Hexose    facilitated  glucose   bidirectional  Pardridge et al., 1990 
Monocarboxylic acid  active   lactate    bidirectional  Conn et al., 1983 
Large neutral amino   
acid (LNAA)  facilitated  phenylalanine   bidirectional  Oldendorf and Szabo, 1976 
Pantothenic acid  facilitated  pantothenic acid  blood-to-brain  Spector et al., 1986 
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Purine    facilitated  adenine      Cornford and Oldendorf, 1975 
Pyrimidines   facilitated  thymidine      Thomas and Segal, 1997  
Taurine   active   taurine    bidirectional  Tamai et al., 1995 
Thiamine   facilitated  thiamine       Greenwood et al., 1982  
Thyroid hormone  facilitated  thyroid hormone     Pardridge, 1979 
_______________________________________________________________________________________________________________ 
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Table 2.  Blood-brain barrier peptide transport systems. 
Carrier   Type   Substrate   Direction  Reference 
_______________________________________________________________________________________________________________ 
Corticotropin-releasing  
hormone (CRH) active   CRH    brain-to-blood  Martins et al., 1996 
D-[Ala1]-peptide T-amide facilitated  D-[Ala1]-peptide T-amide blood-to-brain  Barrera et al., 1987 
Deltorphin   facilitated  deltorphin   blood-to-brain  Fiori et al., 1997 
[D-Penicillamine2,5]- 
enkephalin (DPDPE)    DPDPE   blood-to-brain  Thomas et al., 1997 
Glutathione   active   glutathione   bidirectional  Kannan et al., 1996 
Cytokines      interleukin-1    bidirectional  Banks et al., 1989 
Leucine enkephalin     leucine enkephalin     Zlokovic et al., 1987 
Luteinizing hormone-releasing 
hormone (LHRH) facilitated  LHRH    bidirectional  Barrera et al., 1991 
Neurotensin   facilitated  neurotensin      Banks et al., 1995 
Somatostatin      somatostatin   brain-to-blood  Banks et al., 1994 
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Tyrosinated peptides  active   methionine enkephalin  brain-to-blood  Banks and Kastin, 1997 
Vasopressin   facilitated  vasopressin   brain-to-blood   
_______________________________________________________________________________________________________________ 
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Table 3.  Blood-brain barrier macromolecule endocytic and transcytotic systems. 
________________________________________________________________________________ 
Carrier    Type    Reference 
________________________________________________________________________________ 
Amyloid ß-protein    receptor   Poduslo et al., 1997 
Basic peptides    adsorptive    Tamai et al., 1997 
Histone    adsorptive   Pardridge et al., 1989 
Immunoglobulin G 
Albumin   adsorptive (?)   Poduslo et al., 1994 
Insulin     receptor   Duffy and Pardridge, 1987 
Insulin-like growth factor  receptor   Reinhardt and Bondy, 1994 
Low density lipoprotein  receptor   Dehouck et al., 1997 
Lectins    adsorptive   Villegas and Broadwell, 1993 
Leptin      receptors   Banks et al., 1996 
Modified albumins   adsorptive   Kumagai et al., 1987 
Transferrin    receptor   Broadwell et al., 1996; Bradbury, 1997 
______________________________________________________________________________ 
